Skip to main content
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. — Investor Relations & Filings

Ticker · 2395 ISIN · JP3379950003 LEI · 529900C10QR47J2U5R44 T Professional, scientific and technical activities
Open in API
Filings indexed 68 across all filing types
Latest filing 2024-02-02 Report Publication Anno…
Country JP Japan
Listing T 2395

About SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

https://en.snbl.com/

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Recent filings

Filing Released Lang Actions
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the header "第３四半期報告書" (Third Quarter Report) and specifies a reporting period ("第51期第３四半期（自2023年10月１日 至2023年12月31日）"). It also references the Financial Instruments and Exchange Act ("金融商品取引法") and confirms the appropriateness of the filing's contents by the representative director. This structure strongly indicates a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). The document length is very short (638 chars), but the content is the substance of the confirmation regarding the quarterly report itself, not merely an announcement of its publication. Therefore, the classification is IR.
2024-02-02 Japanese
四半期報告書－第51期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the third quarter of the 51st fiscal period, filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and business performance metrics for the period from April 1, 2023, to December 31, 2023. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. 9M 2024
2024-02-02 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically accompanying a Second Quarter Report (Interim Report). It confirms the accuracy of the quarterly report contents. Since it is a formal regulatory filing confirming the validity of a financial report rather than the report itself, and it is a specific regulatory requirement in Japan, it falls under the RNS category as a regulatory filing.
2023-11-07 Japanese
四半期報告書－第51期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for the second quarter of the 51st fiscal period, filed with the Kanto Local Finance Bureau in Japan. It contains detailed financial statements, management analysis (MDA), and business performance data for the period from July 1, 2023, to September 30, 2023. As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. Q2 2024
2023-11-07 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under Article 24-4-8 of the Financial Instruments and Exchange Act of Japan. This is a mandatory internal control certification that accompanies a Quarterly Report (1st Quarter). Since the document is a formal regulatory filing confirming the accuracy of the quarterly report and is not the quarterly report itself, it falls under the category of Regulatory Filings (RNS) as it is a specific legal requirement for Japanese listed companies that does not fit into the other specialized categories.
2023-08-02 Japanese
四半期報告書－第51期第1四半期(2023/04/01－2023/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for Shin Nippon Biomedical Laboratories, Ltd. for the first quarter of the 51st fiscal year (April 1, 2023, to June 30, 2023). It contains detailed financial statements, management analysis (MDA), and corporate information as required by the Financial Instruments and Exchange Act of Japan. Since it is a comprehensive quarterly financial report containing actual financial data and analysis, it is classified as an Interim/Quarterly Report (IR). Q1 2024
2023-08-02 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.